Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData, Phase II drugs for Post-Polycythemia Vera Myelofibrosis (PPV-MF) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sabatolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sabatolimab is under development for the treatment of solid tumors including glioblastoma multiforme, gliosarcoma and relapsed or refractory and de novo acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, primary myelofibrosis including post-essential thrombocythemia (ET) (PET-MF) and post-polycythemia vera (PV) myelofibrosis (PPV-MF). It is administered intravenously. The monoclonal antibody acts by targeting T cell immunoglobulin mucin-3 (TIM-3). It is a new molecular entity (NME).
It was also under development for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, renal cell carcinoma.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Sabatolimab’s drug-specific PTSR and LoA scores, buy the report here.